[1] 高玖鸣,王文.高血压及心脑血管疾病流行病学的最新数据:美国心脏病和卒中年报2008[J].中华高血压杂志,2009,17(6):494-495. [2] Wang Y,Wang Y,Zhao X,et al.Clopidogrel with aspirin in acute minor stroke or transient ischemic attack[J]. N Engl J Med,2013,369(1):11-19. [3] Johnston S C,Easton J D,Farrant M,et al.Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA[J].N Engl J Med,2018,379(3):215-225. [4] Shulga O,Bornstein N.Antiplatelets in secondary stroke prevention[J].Front Neur,2011,2:36. [5] Mejin M,Tiong W N,Lai L Y H,et al.CYP2C19 genotypes and their impact on clopidogrel responsiveness in percutaneous coronary intervention[J].Int J Clin Pharm,2013,35(4):621-628. [6] Edwards A,Jakubowski J A,Rechner A R,et al.Evaluation of the INNOVANCE PFA P2Y test cartridge:Sensitivity to P2Y12 blockade and influence of anticoagulant[J].Platelets,2012,23(2):106-115. [7] 中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组.中国急性缺血性脑卒中诊治指南2014[J].中华神经科杂志,2015,48(4):246-257. [8] Lim H H,Li S H,An G D,et al.Platelet function analyzer-200 P2Y results are predictive of the risk of major adverse cardiac events in Korean patients receiving clopidogrel therapy following acute coronary syndrome[J].Ann Lab Med,2018,38(5):413-419. [9] Agarwal S,Coakely M,Reddy K,et al.Quantifying the effect of antiplatelet therapy A comparison of the platelet function analyzer (PFA-100 ®) and modified thromboelastography (mTEG ®) with light transmission platelet aggregometry[J].Anesthesiology,2006,105(4):676-683. [10] Chen Z M,Jiang L X,Chen Y P,et al.Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction:randomised placebo-controlled trial[J].Lancet,2005,366(9497):1607-1621. [11] 陶涛,王曙霞,王浩,等.氯吡格雷抵抗与老年急性冠状动脉综合征患者心血管事件相关性研究[J].华西医学,2014,29(8):1439-1442. [12] 赵磊,徐双,贾玫.TEG法与吸光度比浊法对ACS患者PCI术后CLR的诊断价值及临床分析[J].中华检验医学杂志,2016,39(3):187-191. [13] van Diemen J J K,Fuijkschot W W,Wessels T J,et al.Evening intake of aspirin is associated with a more stable 24-h platelet inhibition compared to morning intake:a study in chronic aspirin users[J].Platelets,2016,27(4):351-356. [14] 田奎朋,关杰,蔡力力,等.PFA P2Y评价服用氯吡格雷的老年心血管病患者的血小板功能[J].南方医科大学学报,2017,37(4):533-536. [15] Li S H,Choi J L,Guo L Z,et al.Correlation betw een the CYP2C19 phenotype status and the results of three different platelet function tests in cardiovascular disease patients receiving antiplatelet therapy:an emphasis on newly introduced platelet function analyzer-200 P2Y test[J].Ann Lab Med,2016,36(1):42. [17] 石国霰. 急性脑梗死患者氯吡格雷抵抗与同型半胱氨酸的相关性分析[J].深圳中西医结合杂志,2017,27(9):29-30. [18] 吴金龙,钟池,王磊,等.急性脑梗死患者氯吡格雷抵抗的相关因素研究[J].卒中与神经疾病,2016,23(6):395-398. [19] 陈健,卢英民,黄达民,等.急性冠脉综合征患者PCI术后氯吡格雷抵抗的危险因素分析[J].心血管康复医学杂志,2013,22(2):176-179. [20] 谢文剑,黄贝贝,殷蒨,等.lncRNA在冠心病氯吡格雷抵抗患者中的差异性表达[J].中南大学学报(医学版),2019,44(1):9-13. [21] Larsen E,Celi A,Gilbert G E,et al.PADGEM protein:a receptor that mediates the interaction of activated platelets with neutrophils and monocytes[J].Cell,1989,59(2):305-312. [22] 李平,张巧莲,李双英.脑梗死患者血浆同型半胱氨酸水平与脑动脉狭窄的相关性分析[J].中国基层医药,2015,22(15):2272-2274. [23] Raut M,Maheshwari A.Hyperhomocysteinemia and left ventricular Thrombus[J].Ann Card Anaesth,2017,20(2):276. |